Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

The objective of this double-blinded longitudinal study is to determine whether carnosine supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. In this pilot study we will enroll 144 participants that will be divided into placebo (n=72) and carnosine groups (n=72). We will measure the distance covered on the 6-minute walk test (6-MWT) and the pain free walking capacity on the treadmill before and after the placebo or carnosine supplementation. We will measure ankle branchial index (ABI) and blood flow by magnetic resonance imaging (MRI) before and after the carnosine and placebo supplementation. In addition, we will measure carnosine by 1HMRS (Proton magnetic resonance spectroscopy), perform, global metabolomics and proteomics in the skeletal muscle, a comprehensive lipid and metabolic profile of blood, uptake of carnosine in red blood cells (RBCs), and measure carnosine aldehyde conjugates in the urine before and after 6 months of carnosine and placebo supplementation. Following completion of the study, we will follow the participants for another 3 months and examine the durability of carnosine supplementation.

Inclusion criteria

• Participants between 40-80 years of age.
• White or African American race.
• Literate in English.
• ABI >0.4-<0.90, obtained within 6 weeks from enrollment.
• Willing and able to comply with protocol requirements.
• Participant is able to provide informed consent.

Exclusion criteria

• As per physician's discretion, participants with HIV, hepatitis, significant liver disease, anemia, renal disease requiring dialysis, lung disease requiring home oxygen therapy, and active cancer may be excluded.
• Critical limb ischemia with below or above the knee amputations or any form of foot ulceration over the symptomatic leg.
• Presence of significant injury within 30 days, or vascular intervention on the symptomatic leg within 6 months before enrollment, as per physician's discretion.
• Participants with a baseline 6MWT of less than 152.0 meters (498ft) or greater than 487.7 meters (1600ft).
• Known allergy to L-carnosine.
• Participants with rare autosomal recessive metabolic disorder carnosinemia or carnosinase deficiency.
• Currently participating in other clinical trials.
• Participation in any carnosine supplementation clinical trial anytime in the past.
• Participants already taking carnosine.
• Participants unable to provide urine sample (anuric).
• Pregnant participants.
• Participants using dual antiplatelet therapies will not be included for biopsy.
• Participants with internal metallic objects in body will not be eligible for MRI or 1HMRS.